what a short !
wow do the DD
Adam F what a fool !
Anavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA
Anavex Life Sciences Corp.
3 hours ago
NEW YORK, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program for ANAVEX 2-73. Guidance received from the FDA confirms the Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial.
Way too cheap here, All in baby.
Sentiment: Strong Buy
November 17, 2015
AstraZeneca gains from rival’s trial setback
Bryce Elder Bryce Elder
Clovis Oncology of the US said the number of patients confirmed to be responding to its experimental treatment for lung cancer, rociletinib, was much lower than previously indicated. Its drug has been seen as the main rival of Tagrisso, AstraZeneca’s potential blockbuster, which on Friday unexpectedly won early approval from the US regulator. “Rociletinib now looks likely to be delayed and has a materially inferiorprofileto Tagrisso,” said Deutsche Bank. Deutsche had been forecasting Tagrisso sales of $1bn which it said now looked conservative. Dependent on more trials, the sales opportunity could be as big as $2.5bn to$3bn
Clovis price target cut to $28 from $92 at Piper Jaffray
Piper Jaffray analyst Charles Duncan cut his price target for shares of Clovis Oncology (CLVS) to $28 from$92 after the company announced that rociletinib efficacy data matured and the number of patients with a confirmed response is lower than expected.